[HTML][HTML] A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain
JP Jansen, D Lorch, J Langan, B Lasko, K Hermanns… - The Journal of …, 2011 - Elsevier
Gastrointestinal (GI) side effects are common with opioid medication, and constipation
affects∼ 40% of patients. Such symptoms considerably impair patients' quality of life.
Alvimopan is an orally administered, systemically available, peripherally acting mu-opioid
receptor (PAM-OR) antagonist approved in the US for short-term, in-hospital management of
postoperative ileus in patients undergoing bowel resection. This double-blind, placebo-
controlled trial was conducted as part of a recently discontinued clinical program, in which …
affects∼ 40% of patients. Such symptoms considerably impair patients' quality of life.
Alvimopan is an orally administered, systemically available, peripherally acting mu-opioid
receptor (PAM-OR) antagonist approved in the US for short-term, in-hospital management of
postoperative ileus in patients undergoing bowel resection. This double-blind, placebo-
controlled trial was conducted as part of a recently discontinued clinical program, in which …